When a terminally ill patient is admitted to a hospital in the United States, they typically lose access to a medicine that may have been managing their pain, nausea, and anxiety for months or years. Medical cannabis, even when legally authorized by a state program and recommended by a physician, is almost universally prohibited inside hospitals, nursing homes, and hospice facilities. The reason is straightforward: cannabis remains a Schedule I controlled substance under federal law, and healthcare facilities that receive Medicare and Medicaid funding risk federal sanctions if they permit its use on their premises.

That reality is now being challenged in state legislatures across the country. In February 2026, the Washington State Senate Ways and Means Committee approved a bill that would allow terminally ill patients to use medical cannabis in hospitals, nursing homes, and hospice facilities. Washington is not alone. Similar legislation is advancing in several other states, reflecting a growing consensus that the federal prohibition creates an unacceptable gap in care for patients who are dying.

The implications for palliative medicine, institutional policy, and the broader relationship between state and federal cannabis law are significant.

The Access Gap: What Happens When Patients Are Admitted

The scope of this problem is not widely understood outside of palliative care circles. In the 38 states that have legalized medical cannabis, hundreds of thousands of patients use cannabinoid-based medicines to manage symptoms associated with cancer, neurodegenerative diseases, chronic pain syndromes, and other conditions that frequently lead to hospitalization and end-of-life care. Many of these patients have used cannabis-based therapies for years, often as part of a carefully managed symptom control regimen that their outpatient physicians have endorsed.

The moment these patients are admitted to an inpatient facility, their cannabis access ends. Hospitals cannot store, dispense, or administer cannabis products. Nursing staff cannot assist patients with cannabis use. In most facilities, patients cannot even possess cannabis products on the premises without risking discharge or other consequences.

The clinical result is abrupt discontinuation of a therapy that was working. For a patient with advanced cancer who has been using cannabis to manage breakthrough pain, chemotherapy-induced nausea, and sleep disruption, losing access upon hospital admission means a sudden return of symptoms that must then be managed with alternative pharmaceuticals — often opioids, benzodiazepines, and antiemetics that carry their own substantial side effect profiles.

For terminally ill patients entering hospice care, the situation is particularly stark. Hospice philosophy centers on comfort, dignity, and quality of life during a patient’s final weeks or months. Denying these patients access to a medicine that has been providing symptom relief contradicts the foundational purpose of hospice care.

The Washington Bill: What It Would Do

The Washington legislation is structured narrowly and deliberately. It does not open hospitals to general cannabis use. It applies specifically to patients with a terminal diagnosis — defined in the bill as a medical condition expected to result in death within six months — who hold valid medical cannabis authorizations under Washington state law.

Under the bill, qualifying patients would be permitted to possess and use medical cannabis products within healthcare facilities, subject to facility-specific policies regarding administration methods, storage, and designated use areas. The legislation does not require healthcare workers to administer cannabis or compel any facility to participate. Instead, it removes the legal prohibition that currently prevents facilities from allowing patient-directed cannabis use.

The bill also includes provisions for facility liability protection, a critical element that addresses one of the primary objections raised by hospital administrators and legal counsel. Healthcare facilities that permit cannabis use under the terms of the legislation would be shielded from state-level penalties and licensing consequences.

Smoking and vaporization restrictions within indoor healthcare settings would remain intact under most interpretations, meaning patients would likely use oral preparations such as tinctures, capsules, or edibles — formulations that avoid secondhand exposure concerns and are consistent with existing hospital air quality standards.

The Clinical Evidence for Cannabis in End-of-Life Care

The evidence base for cannabinoid therapies in palliative and end-of-life care spans multiple symptom domains, each supported by varying levels of clinical data.

Pain management. Chronic and acute pain is the most prevalent symptom in terminally ill patients, affecting an estimated 70% to 90% of advanced cancer patients. Cannabinoids exert analgesic effects through CB1 receptor activation in the dorsal horn of the spinal cord and in supraspinal pain processing regions, as well as through anti-inflammatory mechanisms mediated by CB2 receptors in peripheral tissues. A 2023 systematic review in the Journal of Pain and Symptom Management analyzing 14 randomized controlled trials found that adjunctive cannabis-based medicines produced a statistically significant reduction in pain scores compared to placebo in patients with cancer-related pain who had incomplete responses to optimized opioid therapy. The clinical relevance is substantial: these are patients for whom conventional analgesics have already been maximized, and cannabinoids provide an additional layer of relief.

Nausea and appetite loss. THC’s antiemetic properties are among the most well-established therapeutic effects in cannabinoid medicine. Dronabinol (synthetic THC) has held FDA approval for chemotherapy-induced nausea since 1985 and for AIDS-related anorexia since 1992. In palliative care populations, nausea from disease progression, medication side effects, and gastrointestinal dysfunction is pervasive. Whole-plant cannabis preparations offer faster onset of action than oral dronabinol, particularly when administered sublingually, and patients in palliative care settings consistently report improvements in appetite and food intake — a meaningful quality-of-life factor for patients and their families during end-of-life care.

Anxiety and psychological distress. Terminal diagnoses produce profound psychological suffering. Anxiety, existential distress, depression, and insomnia are nearly universal in patients facing death. Low-dose THC in combination with CBD has shown anxiolytic effects in clinical studies, and observational data from palliative care programs in Canada and Israel — where medical cannabis is integrated into some hospice settings — reports that patients using cannabis experience measurable reductions in anxiety scores and improvements in overall self-reported well-being. A 2024 observational study from an Israeli palliative care program found that 68% of terminally ill patients who initiated cannabis therapy reported clinically meaningful improvements in at least two symptom domains within three weeks.

Opioid reduction. Perhaps the most clinically consequential finding in this space is the consistent association between cannabis use and reduced opioid consumption. Multiple retrospective studies have documented 20% to 35% reductions in opioid dosing among palliative care patients who add cannabis to their regimen. For a dying patient, this does not merely represent a harm reduction statistic — it translates to fewer episodes of opioid-induced constipation, less sedation, reduced respiratory depression risk, and greater preserved cognitive function during their remaining time.

The central tension driving this entire debate is the conflict between state and federal law. Cannabis remains classified as Schedule I under the Controlled Substances Act, meaning the federal government considers it to have no accepted medical use and a high potential for abuse. Healthcare facilities operate under a web of federal regulations tied to Medicare and Medicaid participation, Drug Enforcement Administration registration, and Joint Commission accreditation standards — all of which reference federal drug scheduling.

Hospital administrators and their legal teams have historically cited these federal entanglements as the primary reason for blanket cannabis prohibitions. The concern is not theoretical: a facility that knowingly permits the use of a Schedule I substance on its premises could, in principle, face consequences ranging from loss of federal funding to criminal liability under the Controlled Substances Act.

In practice, the federal government has not pursued enforcement actions against healthcare facilities in legal states for patient cannabis use. But the legal ambiguity is real, and risk-averse institutions — which describes nearly every hospital system in the country — have defaulted to prohibition as the safest course.

The state-level bills now advancing attempt to resolve this tension from the bottom up. By explicitly authorizing cannabis use in healthcare facilities and providing liability shields under state law, legislators are creating a framework that allows facilities to develop cannabis policies without fear of state-level repercussions. The federal risk remains, but proponents argue that the political reality of enforcement makes that risk negligible, particularly for terminally ill patients.

The Joint Commission, which accredits more than 22,000 healthcare organizations in the United States, has not issued explicit guidance on state-legal cannabis use by patients in accredited facilities. This silence has been interpreted conservatively by most hospital compliance departments, but it also means there is no affirmative prohibition in accreditation standards — a gap that state legislation could effectively fill.

How This Could Change the Standard of Care

If Washington and other states succeed in passing these bills, the downstream effects on clinical practice could be substantial. Palliative care physicians and hospice medical directors would, for the first time, be able to incorporate cannabis-based therapies into formal care plans for inpatient and residential patients. This would move cannabis from the shadow of informal patient self-management into the structured medical oversight that characterizes every other aspect of end-of-life care.

Formalized cannabis use in healthcare facilities would also generate clinical data that is currently impossible to collect. When patients use cannabis at home, their dosing, product selection, and symptom responses are largely self-reported and uncontrolled. In a clinical setting, these variables can be documented, monitored, and studied — producing the kind of evidence that both advocates and skeptics agree is needed.

Nursing education and clinical training programs would need to address cannabinoid therapeutics in a way that few currently do. A 2025 survey of nursing programs found that fewer than 15% included any formal instruction on the endocannabinoid system or clinical cannabis use. If nurses are expected to accommodate cannabis use in their facilities, education must follow.

The broader signal is perhaps the most important element. Legislation that permits medical cannabis use for dying patients in hospitals and hospices normalizes cannabis as medicine within the most regulated and scrutinized healthcare environments in the country. It moves the conversation from whether cannabis is medicine to how it should be integrated into clinical care — a distinction that reflects where the evidence and patient experience have been pointing for decades.

For the terminally ill patients at the center of this debate, the argument is uncomplicated. They are dying. Cannabis helps manage their symptoms. The legal and bureaucratic barriers that prevent them from using it during their final days in a hospital bed or hospice room are, in their view, indefensible. The state legislatures that are now acting appear to agree.